Nitric oxide and inhaled steroid dose reduction
To the Editor
Inhaled corticosteroids (ICS) are the mainstay of treatment in asthma and act to reduce airway inflammation, however guidelines recommend titrating ICS dose based on the assessment of symptoms (1) which are not closely associated with airway inflammation (2) . Once symptoms and exacerbations are controlled for at least 3 months, ICS reduction is recommended (3).
However step-down is often not implemented, leaving people over-treated. There are few studies investigating the most appropriate way to reduce ICS dose. Clinical trials suggest that the majority of patients currently treated with ICS plus long acting beta agonists can have their therapy successfully stepped down, but there is no clear evidence on how best to achieve this (4) .
We assessed whether exhaled nitric oxide (FeNO) measurements could predict a loss of symptom control or exacerbation following a reduction in ICS dose in a cohort study of people with well controlled asthma recruited from primary care.
Methods
All participants had an asthma diagnosis recorded in their records, were aged between 18 and 75 years, and had received at least one ICS prescription in the last year. The study was restricted to non-smokers with a less than 10 pack year history. Poorly compliant participants, participants with an asthma exacerbation requiring oral steroids in the previous 12 weeks, or with an Juniper Asthma Control Questionnaire-5 (ACQ ® ) (5) score greater than 1.5 at visit 1 (indicating poor control) were excluded. Ethics approval and written informed consent was obtained.
Participants were seen at the same time of day on four occasions; day 0, 14, 21 and 110. At each visit ACQ, FeNO (Aerocrine Flex flow) and spirometry were performed. Symptoms were assessed using the (ACQ) (6) . Airway inflammation was measured using FeNO at flows of 10, 30, 50, 100, 200 ml/sec; participants were blinded to their FeNO measurements. Differential cell counts were performed on induced sputum. Spirometry was performed. Airway hyperresponsiveness was assessed using methacholine challenge to determine the concentration of methacholine required to provoke a 20% fall in the FEV1 (PC20). Blood tests for differential eosinophil count and IgE were performed. (Figure 1 -on line supplement)
Participants were re-assessed at visit 2; if their ACQ score remained <1.5, and had not increased by more than 0.5, their ICS dose was reduced by 50%. Inhaler types were kept the same.
Participants were asked to take the half dose of ICS for seven days and then return for visit 3.
When participants returned for visit 3 their ACQ-5 score was re-measured.
A loss of control was defined as an increase in ACQ score of greater than 0.5 (the minimal important difference in asthma control (7)). An exacerbation was defined as increasing asthma symptoms requiring a course of antibiotics or oral steroids (8) . All participants who contacted the emergency team were assessed by a physician (blinded to data) within 24 hours and their ACQ recorded; decisions on how to treat were based on BTS guidelines.
Using data from previous studies we estimated that a sample of 154 subjects would provide 80% power to show that a low FeNO, or lack of change in FeNO following ICS reduction could successfully predict stable control (8, 9) . Assuming a 10% drop out rate we aimed to recruit 200 subjects.
We analysed the data in two ways: firstly we assessed whether a low baseline FeNO predicted successful ICS dose reduction; secondly we evaluated whether an increase in FeNO following dose reduction predicted deterioration. We also evaluated whether other clinical measures predicted successful dose reduction at three months. Measures included: Baseline spirometry, methacholine PC20, blood IgE, blood eosinophil count, ACQ score, differential sputum eosinophil and neutrophil count.
Results

participants had their
FeNO level measured at visit 2, and seven days after a 50% reduction in ICS dose (visit 3) ( Table 1) . 128 (67%) participants completed the three month study period 
Baseline FeNO
There were no significant differences in baseline FeNO (visit 2) between those successfully reducing ICS dose and those suffering from a loss of control or exacerbation at any of the five 
Change in FeNO
There was no significant difference in the change in FeNO in the week following ICS reduction (visit 2 to visit 3) between the stable and deterioration groups at the 50ml/sec ( Table 2 ). The mean absolute change between visit 2 and 3 was 1.58 ± 11.9ppb for the stable group and 1.03 ± 14.88ppb for the deterioration group (p=0.80). There were no statistically significant differences in any of the baseline clinical measurements between groups.
Conclusion
Although guidelines recommend a 50% reduction in ICS dose after three months of good symptom control, there is evidence of over treatment with ICS (10), and a reluctance to reduce treatment (11) . Consequently using inflammometry to guide treatment decisions may be beneficial. We addressed previous criticisms by evaluating both individual baseline FeNO and change from baseline. We found that neither baseline FeNO measurements nor change at 7 days following ICS dose reduction could predict which participants would remain stable or lose control over the next 3 months.
In our study participants were not blinded to their treatment allocation and a period of 7 days was used post step down before repeating the FeNO measurements. This design was chosen to reflect real life practice and for maximum future practical benefit. A 50% reduction was chosen as being consistent with guideline recommendations and was felt to be ethically justified.
Our study was well powered to identify any change in FeNO values; the relationship between sputum eosinophilia and FeNO levels is strongest between 100-800mcg of ICS (BDP) equivalent (12); previous studies have shown that ICS dose reductions less than the mean reduction in our study result in an increase in FeNO levels (13); dose-dependent onset and cessation of action of ICS on FeNO levels have been demonstrated, with levels rising after one day of treatment reduction (14) ; and the largest change in FeNO values is found at 400mcg BDP equivalent (15) , the mean value prescribed in our population.
The lack of change in FeNO following dose reduction may be due to one of several factors: i)
FeNO measurements do not correlate well enough with airway inflammation in mild to moderate asthma; ii) ICS dose reduction was not large enough; iii) the episodes of symptomatic loss of control were not due to increased airway inflammation.
In addition to the failure to predict ICS reduction using FeNO we found that none of the baseline clinical indices (including induced sputum, methacholine responsiveness and spirometry) had predictive value for future stability following ICS step down. This has important implications for ICS dose reduction and suggests better methods of identification of those at risk of a loss of control following ICS dose reduction are needed.
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